We found that treatment with sorafenib induced the increase of 4-HNE in HCC cells, while treatment with sorafenib based on TMEM39b knockdown increased the expression of 4-HNE more significantly (Figs. 6M–6P). This evidence concerns the gene TMEM39B and hepatocellular carcinoma.